Gastric Cancer
Conditions
Interventions
Group 2:Apatinib Mesylas combine with Xiaoyan Tang
Group 1:Apatinib 500 mg q.d.
Sponsors
First Affilicated Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old, male or female; 2. The histological and / or cytological diagnosis of late gastric cancer; 3. surgery and / or radiotherapy and chemotherapy treatment failed for late gastric cancer; 4. ECOG PS: 0-2 minutes 5. major organs functioning properly, meet the following requirements: (1) blood tests, subject to (not transfusion within 14 days): HB=90g/L; ANC =1.5×10^9/L; PLT =80×10^9/L; (2) biochemical tests must meet the following criteria: BIL <1.5 times the upper limit of normal (ULN); ALT and AST <2.5 × ULN; if liver metastases, the ALT and AST <5 × ULN; Serum Cr=1 × ULN, creatinine clearance rate =50ml / min (Cockcroft-Gault formula); 6. The expected survival =3 months; 7. The treating physician plans to use the APA imatinib mesylate tablets therapy; 8. The patient voluntarily joined the study, and informed consent (ICF); 9. Women of childbearing age must be enrolled in the 7 days before a pregnancy test (serum or urine) results were negative, and the voluntary during the observation period and after the last administration for Nepalese Apa sheet 8 weeks using appropriate methods of contraception; for men, surgical sterilization should be, or agreed during the observation period and after the last administration for Nepalese Apa sheet 8 weeks using appropriate methods of contraception.
Exclusion criteria
Exclusion criteria: 1. suffering from hypertension, the antihypertensive drug therapy can not be reduced to the normal range (systolic blood pressure> 140 mmHg / diastolic blood pressure> 90 mmHg), with =level II of coronary heart disease, arrhythmia (including QTc interval prolongation men> 450 ms, female> 470 ms) and heart failure; 2. With a variety of factors influence oral absorption (such as inability to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction); 3. Special Note: The patient has a risk of gastrointestinal bleeding can not be enrolled, including the following: (1) with active peptic ulcer lesions and fecal occult blood (+); with black stools; (2) 3 months, vomiting a history; (3) for fecal occult blood (+) - and the primary gastric tumor lesions did not undergo surgery, the need for endoscopy, such as gastric ulcer, and the treating physician believes it may cause bleeding lesions; 4. coagulopathy (INR> 1.5 × ULN, APTT> 1.5 × ULN), have bleeding tendencies; 5. The transfer of the central nervous system with symptoms; 6. A pregnant or lactating women; 7. Other treating physicians considered unsuitable for patients included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS;The rate of advers reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| os;ORR;DCR; | — |
Countries
China
Contacts
Public ContactJia Yingjie
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed